Schonfeld Strategic Advisors LLC Acquires 17,231 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Schonfeld Strategic Advisors LLC increased its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 384.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,708 shares of the medical research company's stock after purchasing an additional 17,231 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Exact Sciences were worth $1,220,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Asset Planning Inc purchased a new position in shares of Exact Sciences during the 4th quarter valued at about $40,000. AlphaQuest LLC lifted its holdings in shares of Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after acquiring an additional 913 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Exact Sciences in the 4th quarter valued at $66,000. Ostrum Asset Management grew its holdings in shares of Exact Sciences by 28.4% during the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after purchasing an additional 527 shares during the last quarter. Finally, Kieckhefer Group LLC purchased a new position in Exact Sciences in the 4th quarter worth $188,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on EXAS shares. Bank of America decreased their price objective on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Robert W. Baird boosted their price objective on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Barclays raised their target price on shares of Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Royal Bank of Canada upped their price target on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Finally, Benchmark reissued a "buy" rating and issued a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Trading Down 1.4 %

NASDAQ:EXAS opened at $53.25 on Thursday. The firm has a market capitalization of $10.04 billion, a P/E ratio of -9.56 and a beta of 0.92. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. Exact Sciences Co. has a one year low of $39.97 and a one year high of $72.83. The company's 50-day simple moving average is $45.36 and its 200 day simple moving average is $53.07.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. The firm had revenue of $706.79 million for the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.60) EPS. As a group, analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.